Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

Studies Show Agendia Assay Could Reduce
Unnecessary Chemo for Node +/- Patients

[December 19, 2007]

By Turna Ray

An international consortium has shown that Agendia’s MammaPrint breast cancer prognosis test can accurately identifying which lymph node-positive breast cancer patients should not receive adjuvant chemotherapy. The company also recently published data showing how the test can reduce chemotherapy treatment in node-negative breast cancer patients, and completed a study that shows it might be useful in determining the treatment for elderly patients.

Login | Subscribe